Mirador Therapeutics–SEVERAL: investment, 202403 emerges with >$400m in financing led by ARCH Venture with early investments by OrbiMed + Fairmount

	Period	2024-03-21
	Money taker	Mirador Therapeutics Inc.
	Money source	SEVERAL
	Product	Mirador360™ precision development engine
	Product 2	venture capital
	Person	Burow, Kristina (ARCH Venture Partners 201903 Managing Directorm joined 2002)
	Person 2	Berns, Paul L. (ARCH Venture 202101 Partner previously Venture Partner before Anacor Pharmaceuticals + Allos Tx)

Mirador Therapeutics, Inc.. (3/21/24). "Press Release: Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases". San Diego, CA.

> Rapidly advancing multiple therapeutic programs leveraging Mirador360 TM precision development engine incorporating advances in human genetics and cutting-edge data science

> Company led by several former executives of Prometheus Biosciences and founded by chairman and CEO Mark C. McKenna

> Over $400 million in financing led by ARCH Venture Partners with early investments from OrbiMed and Fairmount and participation from other premier life sciences investors

Mirador Therapeutics, Inc. (Mirador) announced its launch today. Founded by Mark C. McKenna and led by several former executives of Prometheus Biosciences (acquired in 2023 by Merck for $10.8 billion), Mirador aims to revolutionize precision medicine for immune-mediated inflammatory and fibrotic diseases by leveraging its proprietary Mirador360™ development engine to rapidly advance multiple programs. Mirador has raised more than $400 million in financing led by ARCH Venture Partners, with early investments from OrbiMed and Fairmount. Other premier life sciences investors also participated, including Fidelity Management & Research Company, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Sanofi Ventures, Woodline Partners LP, Venrock Healthcare Capital Partners, RTW Investments and Alexandria Venture Investments.

“At Mirador, we envision a bold new era of precision medicine for immune-mediated inflammatory and fibrotic diseases driven by speed and superior development accuracy,” said Mark C. McKenna, chairman and CEO of Mirador. “The industry has only scratched the surface of utilizing advances in human genetics – coupled with exponential progress in machine learning – to accelerate the development of precision therapies for patients who need them the most. With a proven team, distinguished board of directors, leading healthcare investors and proprietary data-driven approach, we aim to create a leading precision medicine company at scale to provide important new treatment options for patients.”

“The I&I field is in need of better, novel therapeutics as well as new R&D approaches that target enriched patient populations for improved probability of success in the clinic,” said Kristina Burow, Mirador board member and managing director of ARCH Venture Partners. “The Mirador team has an outstanding track record of success in precision immunology, and we are well on our way to building a company that will make a lasting impact on the lives of millions of patients suffering from a broad range of immune-mediated inflammatory and fibrotic diseases.”

The Next Wave of Precision Medicine in Immunology and Inflammation (I&I)

Mirador’s focus is on developing first-in-class or best-in-class precision medicines. To accelerate development, Mirador utilizes Mirador360, its proprietary precision development engine that leverages recent breakthroughs in human genetics and cutting-edge data science. Mirador360 is purpose-built to harmonize millions of patient molecular profiles to discover and validate genetic associations to immuno-fibrotic diseases, identify novel therapeutic targets and elucidate target-target interactions as well as optimal target-target pairs for potential combination therapies. Mirador360 also allows Mirador to develop diagnostics and stratify heterogeneous patient populations for precise clinical development.

About Mirador Therapeutics

Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360™ precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA. For more information, please visit us at www.miradortx.com and follow us on LinkedIn.

Contacts:

Media:

Dan Budwick
1AB
dan@1abmedia.com

Investors:

Steve Klass
1AB
steve@1abmedia.com